April 4, 2017 / 10:12 AM / 4 months ago

BRIEF-Contravir’S Cyclophilin inhibitor CRV431 targets hepatitis B surface antigen (HBSAG)

1 Min Read

April 4 (Reuters) - Contravir Pharmaceuticals Inc

* Contravir’S Cyclophilin inhibitor CRV431 targets hepatitis B surface antigen (HBSAG)

* New studies show that CRV431 potently blocks interaction between hepatitis B surface antigen and Cyclophilin A

* New information could explain previous findings that CRV431 reduces HBSAG in many experimental systems

* Findings further elucidate MOA of CRV431, and support contravir's strategy of providing a "functional cure" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below